State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
College of Life Science, Liaocheng University, Liaocheng, 252059, China.
J Nat Med. 2024 Jun;78(3):618-632. doi: 10.1007/s11418-024-01811-4. Epub 2024 Apr 26.
Acute myeloid leukemia (AML) is a malignant disease that is difficult to completely cure. Polyphyllin I (PPI), a steroidal saponin isolated from Paris polyphylla, has exhibited multiple biological activities. Here, we discovered the superior cytotoxicity of PPI on AML cells MOLM-13 with an IC values of 0.44 ± 0.09 μM. Mechanically, PPI could cause ferroptosis via the accumulation of intracellular iron concentration and triggering lipid peroxidation. Interestingly, PPI could induced stronger ferroptosis in a short time of about 6 h compared to erastin. Furthermore, we demonstrate that PPI-induced rapid ferroptosis is due to the simultaneous targeting PI3K/SREBP-1/SCD1 axis and triggering lipid peroxidation, and PI3K inhibitor Alpelisib can enhance the activity of erastin-induced ferroptosis. Molecular docking simulations and kinase inhibition assays demonstrated that PPI is a PI3K inhibitor. In addition, PPI significantly inhibited tumor progression and prolonged mouse survival at 4 mg/kg with well tolerance. In summary, our study highlights the therapeutic potential of PPI for AML and shows its unique dual mechanism.
急性髓系白血病(AML)是一种难以完全治愈的恶性疾病。从山荷叶中分离得到的甾体皂甙重楼苷 I(PPI)具有多种生物学活性。在这里,我们发现 PPI 对 AML 细胞 MOLM-13 的细胞毒性更强,IC 值为 0.44±0.09μM。在机制上,PPI 通过积累细胞内铁浓度和触发脂质过氧化来引起细胞铁死亡。有趣的是,与 erastin 相比,PPI 可以在更短的时间(约 6 小时)内诱导更强的铁死亡。此外,我们证明 PPI 诱导的快速铁死亡是由于同时靶向 PI3K/SREBP-1/SCD1 轴并触发脂质过氧化,并且 PI3K 抑制剂 Alpelisib 可以增强 erastin 诱导的铁死亡活性。分子对接模拟和激酶抑制试验表明,PPI 是一种 PI3K 抑制剂。此外,PPI 在 4mg/kg 剂量下具有良好的耐受性,显著抑制肿瘤进展并延长了小鼠的存活时间。综上所述,我们的研究强调了 PPI 治疗 AML 的潜力,并展示了其独特的双重作用机制。
Free Radic Biol Med. 2018-12-14
Arch Biochem Biophys. 2020-2-16
Curr Pharmacol Rep. 2024-12
Apoptosis. 2025-6-9
Naunyn Schmiedebergs Arch Pharmacol. 2025-3-31
Front Pharmacol. 2023-4-4
Front Pharmacol. 2022-5-11
Mol Cancer. 2022-2-12